Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AEON Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
AEON
NYSE American
2836
www.aeonbiopharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AEON Biopharma, Inc.
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
- May 23rd, 2025 2:05 pm
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
- May 19th, 2025 2:05 pm
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
- May 14th, 2025 2:05 pm
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
- Apr 25th, 2025 2:05 pm
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
- Apr 21st, 2025 2:05 pm
AEON Biopharma Announces CEO Transition
- Mar 27th, 2025 2:05 pm
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Mar 24th, 2025 2:05 pm
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference
- Mar 4th, 2025 6:00 am
AEON Biopharma, Inc. Announces Reverse Stock Split
- Feb 24th, 2025 12:00 pm
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
- Feb 7th, 2025 2:05 pm
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering
- Jan 7th, 2025 7:37 am
AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
- Jan 6th, 2025 7:00 am
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
- Jan 3rd, 2025 6:02 pm
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 13th, 2024 2:05 pm
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
- Sep 30th, 2024 6:00 am
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Aug 21st, 2024 7:55 am
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
- Aug 19th, 2024 2:05 pm
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Aug 12th, 2024 2:05 pm
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
- Jul 9th, 2024 6:00 am
Scroll